Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
10 evidence topics · 8 sources
Humanized monoclonal antibody that binds KIT and blocks SCF binding and KIT dimerization
Allosteric inhibition through the membrane-proximal dimerization domains of KIT
“CDX‐0159 is a humanized IgG1/κ monoclonal antibody with a modified Fc domain that was derived from CDX‐0158, a predecessor anti‐KIT antibody with an unmodified IgG1/κ backbone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The antibody was developed from mice immunized with the membrane proximal dimerization domains (Ig 4 and 5) of human KIT (huKIT‐D4D5), which are required for KIT activation by SCF but are not directly involved in ligand binding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 bound to KIT naturally expressed in the surface of megakaryoblastic leukemia M‐07e cells with an EC50 of 153 ± 22 pM (Figure 1B), and completely blocked binding of fluorescently labeled SCF to M‐07e cells with an IC50 value of 118 ± 6 pM (Figure 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 allosterically blocks binding of SCF to KIT, which may result in an elevation of SCF plasma levels from accumulating unbound SCF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity and inhibition of SCF-dependent KIT phosphorylation and mast cell degranulation
“Furthermore, CDX‐0159 bound specifically to KIT but not to other related type‐III receptor tyrosine kinases (Figure S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, titration of CDX‐0159 on CHO cells stably transfected to express human KIT (CHO‐KIT) inhibited SCF‐dependent KIT phosphorylation (Figure 1D) with an IC50 of 232 ± 4 pM, or 2–3 orders of magnitude more potently than FDA‐approved KIT‐targeting TKIs imatinib, pexidartinib, and avapritinib (IC50 = 931 ± 78 nM, 87 ± 7 nM, and 175 ± 59 nM, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this assay, CDX‐0159 titration fully inhibited SCF‐dependent MC degranulation (IC50 = 650 ± 88 pM) (Figure 1F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fc substitutions that abolish effector function and reduce clearance
“To eliminate the potential for FcγR crosslinking and effector functions, we engineered 3 amino acid substitutions (L234A/L235Q/K322Q) in the Fc region of CDX‐0158 predicted to abolish FcγR binding and expected to similarly impact C1q receptor binding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, we also incorporated a set of modifications (M252Y/S254T/T256E)—herein named YTE—that increase the binding affinity for the neonatal Fc receptor (FcRn) which enhances the pharmacokinetic (PK) properties of the mAb by reducing the rate of in vivo clearance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taken together, these data demonstrate that the Fc modifications in CDX‐0159 effectively abolish Fc‐dependent effector function and agonist activity leading to MC degranulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KIT expression on mast cells and on other cell types
“The KIT (c‐KIT/CD117) receptor tyrosine kinase and its only ligand stem cell factor (SCF) are master regulators of MC biology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“KIT is highly expressed throughout the life of a MC and is also expressed in hematopoietic stem cells, melanocytes, interstitial cells of Cajal, germ cells, and a subset of taste receptor cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mast cell depletion as the hypothesized basis of benefit in CSU
“Barzolvolimab—a monoclonal anti‐KIT antibody—depletes MCs by inhibiting activation of KIT by stem cell factor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab, as a potent inhibitor of SCF‐dependent KIT activation in cells, is hypothesized to provide therapeutic benefit in patients with CSU by decreasing the number of MCs and their activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results support the anti‐KIT mechanism of action for treating CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had similar symptom improvement irrespective of prior omalizumab use, suggesting that barzolvolimab can help improve urticaria symptoms regardless of whether IgE is the underlying trigger.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Wild-type and KITD816V mast cell models: apoptosis and SCF-enhanced IgE-mediated activation
“We established and characterized primary-like human MC models, including isogenic human induced pluripotent stem cell-derived WT and heterozygous KITD816V MCs, peripheral CD34+ stem cell-derived MCs, and HMC-1.2 cell line.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab induced dose-dependent apoptosis and inhibited stem cell factor-induced KIT signaling in WT MCs, but it had no effect on mutant MC viability or signaling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, barzolvolimab effectively suppressed stem cell factor-enhanced IgE-mediated MC activation across all primary-like models, including KITD816V MCs, as evidenced by reduced β-hexosaminidase release and CD63 expression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This inhibitory effect occurred at low nanomolar concentrations and was independent of cytotoxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote